On this episode of Stock Movers:

- Advanced Micro Devices (AMD) shares rise after news that Meta Platforms will deploy data center gear based on processors from AMD in a deal worth “double-digit billions” of dollars per gigawatt.

- Warner Bros. Discovery (WBD) is considering a new takeover proposal from Paramount Skydance Corp., the latest salvo in a months-long battle for control of one of Hollywood’s most famed studios. The parent of HBO and CNN said its board will review the proposal and respond, according to a statement Tuesday

- Eli Lilly (LLY) shares fall after news Novo Nordisk plans to slash the US list prices for its medicines Wegovy and Ozempic next year. The monthly price will be set at $675, a cut of as much as 50%, to make the medicines more competitive in the obesity market.

 

On this episode of Stock Movers:
- Advanced Micro Devices (AMD) shares rise after news that Meta Platforms will deploy data center gear based on processors from AMD in a deal worth &ldquo;double-digit billions&rdquo; of dollars per gigawatt.
- Warner Bros. Discovery (WBD) is considering a new takeover proposal from Paramount Skydance Corp., the latest salvo in a months-long battle for control of one of Hollywood&rsquo;s most famed studios. The parent of HBO and CNN said its board will review the proposal and respond, according to a statement Tuesday
- Eli Lilly (LLY) shares fall after news Novo Nordisk plans to slash the US list prices for its medicines Wegovy and Ozempic next year. The monthly price will be set at $675, a cut of as much as 50%, to make the medicines more competitive in the obesity market.
&nbsp;

Listen for five-minute conversations on today's biggest winners and losers in the stock market. 

Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for five-minute conversations on today's biggest winners and losers in the stock market.&nbsp;
Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Advanced Micro Devices Rises, Warner Bros. Discovery Mixed, Eli Lilly Drops on Novo Plans to Slash US List Prices for Weight-Loss Drugs

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/900b7938-9d62-4c6c-8231-b3fb00fdf860/transcript

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Diageo cut its guidance for the second time this fiscal year as the British distiller struggles to revive demand in the US and China, in an early challenge for new Chief Executive Officer Dave Lewis.
- Banco Santander vowed to grow net income to more than €20 billion ($23.6 billion) in 2028, ratcheting up its financial goals shortly after announcing the acquisition of US lender Webster Financial Corp. 
- Trainline shares fall as much as 8.5%, hitting the lowest level since March 2022, after the online train ticketing platform announced that CEO Jody Ford intends to step down after five years in the role. The change of leadership is “untimely,” according to JPMorgan analysts.

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Diageo cut its guidance for the second time this fiscal year as the British distiller struggles to revive demand in the US and China, in an early challenge for new Chief Executive Officer Dave Lewis. - Banco Santander vowed to grow net income to more than &euro;20 billion ($23.6 billion) in 2028, ratcheting up its financial goals shortly after announcing the acquisition of US lender Webster Financial Corp. - Trainline shares fall as much as 8.5%, hitting the lowest level since March 2022, after the online train ticketing platform announced that CEO Jody Ford intends to step down after five years in the role. The change of leadership is &ldquo;untimely,&rdquo; according to JPMorgan analysts.

Dismal Diageo, Santander's Vow, Trainline's Exit

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:
- HSBC reported better-than-estimated earnings for 2025 as Europe’s largest bank closed out a year in which its market value broke through £200 billion ($270 billion) for the first time in its history.
- Aston Martin will cut as much as a fifth of its roughly 3,000 workforce, as the ailing luxury-car maker grapples with an elusive turnaround made harder by US President Donald Trump’s tariffs.
- Diageo cut its guidance for the second time this fiscal year as the British distiller struggles to revive demand in the US and China, in an early challenge for new Chief Executive Officer Dave Lewis.

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - HSBC reported better-than-estimated earnings for 2025 as Europe&rsquo;s largest bank closed out a year in which its market value broke through &pound;200 billion ($270 billion) for the first time in its history. - Aston Martin will cut as much as a fifth of its roughly 3,000 workforce, as the ailing luxury-car maker grapples with an elusive turnaround made harder by US President Donald Trump&rsquo;s tariffs. - Diageo cut its guidance for the second time this fiscal year as the British distiller struggles to revive demand in the US and China, in an early challenge for new Chief Executive Officer Dave Lewis.

HSBC Up, Aston Martin Cuts, Dismal Diageo 

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:
- Cava Group (CAVA) reported fourth-quarter sales growth and gave a rosy outlook for 2026, outperforming its fast-casual rivals and bucking expectations for a slowdown. Sales from established restaurants are seen expanding 3% to 5% this year, with the company citing price increases and customers opting for more expensive options as helping to offset a decline in store visits. Cava shares jumped 9.2% after the close of regular trading in New York, with the stock having advanced nearly 16% so far this year.

- PayPal (PYPL) closed up 6.7% to $47.01 in New York Tuesday, giving it a market value of $43.3 billion after Bloomberg reported that Stripe is considering an acquisition of all or parts of PayPal Holdings Inc., according to people familiar with the matter. The deliberations are early and there's no certainty they'll lead to a transaction, the people said.

- Novo Nordisk (NOV) next-generation weight-loss drug CagriSema had disappointing trial results, sparking calls for a radical shift in the company's strategy. Some investors are urging Novo to diversify away from diabetes and obesity, citing the risk of relying on these two areas, and suggesting fields such as rare diseases, heart disease, or cancer treatment.

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Cava Group (CAVA) reported fourth-quarter sales growth and gave a rosy outlook for 2026, outperforming its fast-casual rivals and bucking expectations for a slowdown. Sales from established restaurants are seen expanding 3% to 5% this year, with the company citing price increases and customers opting for more expensive options as helping to offset a decline in store visits. Cava shares jumped 9.2% after the close of regular trading in New York, with the stock having advanced nearly 16% so far this year. - PayPal (PYPL) closed up 6.7% to $47.01 in New York Tuesday, giving it a market value of $43.3 billion after Bloomberg reported that Stripe is considering an acquisition of all or parts of PayPal Holdings Inc., according to people familiar with the matter. The deliberations are early and there's no certainty they'll lead to a transaction, the people said. - Novo Nordisk (NOV) next-generation weight-loss drug CagriSema had disappointing trial results, sparking calls for a radical shift in the company's strategy. Some investors are urging Novo to diversify away from diabetes and obesity, citing the risk of relying on these two areas, and suggesting fields such as rare diseases, heart disease, or cancer treatment.

Advanced Micro Devices Rises, Warner Bros. Discovery Mixed, Eli Lilly Drops on Novo Plans to Slash US List Prices for Weight-Loss Drugs

Stock Movers

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips